MRK - Merck & Co., Inc.
79.39 -0.11 (-0.14%)
After hours: 6:03PM EDT
| Previous Close | 78.88 |
| Open | 79.08 |
| Bid | 79.30 x 3100 |
| Ask | 79.80 x 800 |
| Day's Range | 78.53 - 79.73 |
| 52 Week Range | 58.03 - 83.85 |
| Volume | 10,104,227 |
| Avg. Volume | 10,353,135 |
| Market Cap | 204.684B |
| Beta (3Y Monthly) | 0.31 |
| PE Ratio (TTM) | 25.10 |
| EPS (TTM) | 3.17 |
| Earnings Date | Jul 30, 2019 |
| Forward Dividend & Yield | 2.20 (2.80%) |
| Ex-Dividend Date | 2019-03-14 |
| 1y Target Est | 88.07 |
- Barrons.com•6 hours ago
Merck Snaps Up Cancer Drugmaker Peloton Therapeutics
American pharmaceutical giant Merck & Co. said it is buying Peloton Therapeutics, a clinical-stage biopharmaceutical company, for $1.05 billion in cash.
GuruFocus.com•9 hours agoThese 3 Major Drug Manufacturers Are Strong Performers
Roche Holding AG (RHHBY) has climbed 2.4% over the last week, 0.5% over the past month, 5.7% so far this year, 17.6% over the last 52 weeks and 5.3% over the past three years through May 20. Warning! GuruFocus has detected 3 Warning Signs with RHHBY. Currently, the company is paying an annual dividend of $1.07 per common share, which, based on the closing share price on May 20, leads to a forward dividend yield of 3.27% versus the industry median of 1.66%.
- American City Business Journals•12 hours ago
After filing an IPO, Dallas company to sell to Merck for $1.05 billion
DFW company, had filed to go public less than a month ago, could see shareholders get additional $1.15 billion
Reuters•12 hours agoMerck buys Peloton to expand its kidney cancer treatment portfolio
The acquisition can strengthen Merck's presence in the field of renal cell carcinoma and bolster its cancer drug portfolio. Merck's blockbuster immunotherapy Keytruda was approved last month in the United States for treating renal cell cancer.
- Bloomberg•12 hours ago
Merck to Buy Peloton for Up to $2.2 Billion, Day Before IPO
Merck will pay $1.05 billion in cash, plus $1.15 billion in additional payments based on how the small company’s experimental drugs fare as they are developed further by Merck, the firms said in a statement announcing the deal Tuesday. The deal offers an immediate payout for Peloton’s investors, including Dallas-based venture capital firm Remeditex Ventures and San Francisco’s The Column Group. At the $17 high range of Peloton’s expected initial public offering, the market would have valued the company at $756 million.
- Benzinga•12 hours ago
Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B
Merck & Co., Inc. (NYSE: MRK ) announced an agreement Tuesday to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion in ...
- TheStreet.com•13 hours ago
Merck to Acquire Peloton Therapeutics for About $1B in Cash
on Tuesday said it agreed to buy privately held Peloton Therapeutics for about $1 billion in cash, giving it access to Peloton's molecular therapy biotech treatments currently in development for patients with cancer and other non-oncology diseases. Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Peloton in exchange for an upfront payment of $1.05 billion in cash, the company said. Peloton shareholders also will be eligible to receive a further $1.15 billion contingent upon successful achievement of future regulatory and sales milestones for certain candidates.
- American City Business Journals•14 hours ago
Merck to buy cancer drug developer in deal that could be worth more than $2B
Merck's deal for Dallas-based Peloton Therapeutics includes an upfront payment of $1.05 billion.
- Zacks•14 hours ago
Merck's Keytruda Fails in Late-Stage Breast Cancer Study
Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.
- MarketWatch•16 hours ago
Merck to acquire Peloton Therapeutics for upfront payment of $1.05 billion in cash
Merck & Co. Inc. said Tuesday it has reached an agreement to acquire Peloton Therapeutics Inc. for an upfront payment of $1.05 billion in cash. Peloton, a clinical-stage biotech focused on cancer treatments, was expected to price an initial public offering on Wednesday. The biotech's business hinges instead on two drugs that are designed to block a transcription factor called hypoxia-inducible factor-2 alphaαthat - among other things - regulates how the body responds to low oxygen levels. Under the terms of the deal, Peloton shareholders will be entitled to a further $1.15 billion in milestone payments based on the achievement of certain future regulatory and sales goals. "This acquisition exemplifies Merck's strategy to pursue novel therapeutic candidates based on exceptionally promising and innovative research," said Dr. Roger M. Perlmutter, president of Merck Research Laboratories. "Peloton scientists have applied their unique expertise in HIF-2α biology to develop PT2977, which has already shown intriguing activity in the treatment of renal cell carcinoma. We look forward to advancing this late-stage asset as part of our broad oncology R&D program." The deal is expected to close in the third quarter. Merck shares were not active premarket, bu have gained 34.7% in the last 12 months, while the S&P 500 has gained 3.9%.
- Business Wire•16 hours ago
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
Merck (MRK), known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC).
- Investing.com•18 hours ago
Stocks - Kohls, JC Penny, Tesla Fall Premarket; Boeing Rises
Investing.com - Stocks in focus in premarket trading on Tuesday:
- CNBC•yesterday
Stocks making the biggest moves after hours: GM, Snap, Merck and more
Shares of Merck & Co MRK dropped as much as 9% in extended trading on Monday, before erasing those losses, after the pharmaceutical company announced that its medication Keytruda failed to meet expectations in phase 3 of the drug's trial. Shares of Snap SNAP ticked slightly higher after the company announced it has named a new chief financial officer to take over for interim CFO Lara Sweet, effective immediately. The social media company promoted Derek Andersen, Snap's current vice president of finance, to permanently fill the position of chief financial officer.
- Reuters•yesterday
Merck's Keytruda fails as monotherapy in breast cancer study
Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer. Keytruda, among a class of medicines called PD-1 inhibitors, did not meet the main goal of helping patients live longer, when compared to chemotherapy. The treatment will continue to be studied in earlier stages of the disease and in combination with chemotherapy in patients with triple negative breast cancer, the company said.
- MarketWatch•yesterday
Merck shares slip as Keytruda fails another clinical trial
Merck & Co. shares slipped in the extended session Monday after the drug maker said its cancer treatment Keytruda failed to meet clinical endpoints in another late-stage study. Merck shares declined 0.7% after hours, following a 0.2% rise to close the regular session at $78.88. In a Phase 3 clinical study, Merck said Keytruda "did not meet its pre-specified primary endpoint of superior overall survival" compared with chemotherapy in a subset of breast cancer patients. In late April, Merck said Keytruda did not show significant improvement over chemotherapy in gastric cancer patients. For the year, Merck shares are up 3.2%, compared with a 13.3% rise in the S&P 500 index .
- Business Wire•yesterday
Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
Merck , known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy .
- Reuters•yesterday
U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits
The U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation. The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision to let the lawsuits proceed even though the Food and Drug Administration had rebuffed Merck when the company sought to add a warning to Fosamax's label about fracture risk.
- Zacks•2 days ago
Why Merck (MRK) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks•2 days ago
AbbVie's Brain Cancer Candidate Fails in Phase III Study
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
- Reuters•2 days ago
CPPIB buys partial Keytruda royalty interest from British charity LifeArc
Canada's largest pension fund said the deal was an ideal investment for its global intellectual property programme as Keytruda, an immunotherapy treatment for different cancer types, has shown strong sales growth worldwide. Keytruda, which works by increasing the ability of the patient's immune system to help detect and fight tumour cells, is approved for use in 85 countries and the drug is expected to bring more than $10 billion for Merck this year, according to IBES data from Refinitiv.
- Investopedia•2 days ago
Why Stock Buybacks Are Soaring Near Record Highs Amid Trade War
The largest U.S. companies are repurchasing their shares at a brisk pace, and 1Q 2019 may prove to be the second-biggest quarter ever for buybacks.
- Zacks•5 days ago
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
- Reuters•5 days ago
Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles
Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk. Some legal experts believe Bayer will have a tough time convincing appellate courts to throw out verdicts and lawsuits on those grounds. Bayer has a better shot if a business-friendly U.S. Supreme Court takes up the case, experts said.
